Inclusion Criteria:  Patients 18-85 years; A cytological/histological or radiological diagnosis of inoperable HPB malignancy;  MDT review confirming inoperability.  -Patients who have declined surgery will also be considered for the study.  Medically fit to undergo procedure in opinion of the investigator.  Exclusion Criteria:  Unable to provide free informed consent within 7 days; ECOG performance status 3 or 4; Life expectancy <1 months;  Prior investigational drugs within last 30 days;  - Patients who have already commenced approved chemotherapy regimens are not excluded from the study.  Patients with clinically significant ascites; Patients with CNS metastases; Major surgery within last 30 days;  Patients with active sepsis or encephalopathy;  - Patients may present with biliary sepsis prior to diagnosis. Inclusion of such a patient can be considered once biliary sepsis has been managed as per local Trust guidance.  Evidence of spontaneous bacterial peritonitis or renal failure;  Pregnant or lactating women;  - Females of childbearing potential will undergo a blood pregnancy test to confirm they are not pregnant within 7 days prior to randomisation.  Unstable angina, heart disease or diabetes; Intractable severe blood coagulation dysfunction; Fitted with implantable pacemaker, implantable cardioverter/defibrillator or other active implant; Unable to understand the study information or unable to complete the outcome questionnaires (in English); Un-willing or un-able to comply with all protocol requirements including scheduled visits, treatment plans, laboratory tests and other study procedures; Medically un-fit to undergo procedure in opinion of the investigator.